Home » Stocks » UBX

Unity Biotechnology, Inc. (UBX)

Stock Price: $6.47 USD -0.54 (-7.70%)
Updated Jan 20, 2021 2:04 PM EST - Market open
Market Cap 370.92M
Revenue (ttm) n/a
Net Income (ttm) -92.28M
Shares Out 52.48M
EPS (ttm) -1.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $6.47
Previous Close $7.01
Change ($) -0.54
Change (%) -7.70%
Day's Open 7.20
Day's Range 6.43 - 7.20
Day's Volume 838,154
52-Week Range 2.94 - 12.43

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.

PRNewsWire - 4 weeks ago

SUZHOU, China and ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for c...

GuruFocus - 1 month ago

Big names like Glaxo, Pfizer and Johnson & Johnson also abandoned promising programs

Other stocks mentioned: AUPH
GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse disea...

GlobeNewsWire - 1 month ago

Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY's Board

Seeking Alpha - 1 month ago

Unity Bio was previously advancing a lead candidate aimed at reducing osteoarthritis pain by selectively clearing senescent cells in the knee. This candidate, UBX0101, was dropped by the compa...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases...

GlobeNewsWire - 3 months ago

SAN FRANCISCO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversi...

GlobeNewsWire - 4 months ago

- Corporate restructuring to extend cash runway through mid-2022 and key milestones -

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reve...

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or rever...

Zacks Investment Research - 4 months ago

Unity Biotechnology (UBX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zacks Investment Research - 5 months ago

Unity's (UBX) lead pipeline candidate, UBX0101, fails to meet primary endpoint in a phase II study in patients with moderate-to-severe painful osteoarthritis of the knee.

Benzinga - 5 months ago

Shares of Unity Biotechnology Inc (NASDAQ: UBX), which went public in mid-2018, were moving notably lower Monday following an adverse clinical readout.

The Motley Fool - 5 months ago

The development-stage biopharma announced disappointing results from a clinical trial.

24/7 Wall Street - 5 months ago

Unity Biotechnology Inc. (NASDAQ: UBX) stock was absolutely crushed on Monday after the company announced results from its midstage study in patients with moderate-to-severe painful osteoarthr...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowi...

GlobeNewsWire - 5 months ago

SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversi...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing...

GlobeNewsWire - 5 months ago

SAN FRANCISCO, July 29, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or r...

GlobeNewsWire - 5 months ago

SAN FRANCISCO, July 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or r...

GlobeNewsWire - 6 months ago

Lynne Sullivan appointed interim chief financial officer Lynne Sullivan appointed interim chief financial officer

GlobeNewsWire - 6 months ago

– Topline 12-week results for Phase 2 study of UBX0101 in osteoarthritis expected in 3Q 2020 –

GlobeNewsWire - 7 months ago

SAN FRANCISCO, June 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or rever...

Zacks Investment Research - 7 months ago

Unity Biotechnology, Inc. (UBX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Seeking Alpha - 8 months ago

Unity Biotechnology: A Speculative Play For 2H 2020

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor Unity Biotechnology

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Unity Biotechnology.

GlobeNewsWire - 9 months ago

– Topline 12- and 24-week results expected in 2H 2020 – – Topline 12- and 24-week results expected in 2H 2020 –

GlobeNewsWire - 9 months ago

SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. today announced that Anirvan Ghosh, Ph.D., has officially joined the company as Chief Executive Offi...

GlobeNewsWire - 10 months ago

– Renowned Scientist and Drug Developer Joins UNITY’s Mission to Extend Healthspan  –

GlobeNewsWire - 10 months ago

– Phase 2 study of UBX0101 in patients with osteoarthritis has completed enrollment –

GlobeNewsWire - 10 months ago

SAN FRANCISCO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...

GlobeNewsWire - 1 year ago

SAN FRANCISCO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or r...

GlobeNewsWire - 1 year ago

SAN FRANCISCO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting o...

GlobeNewsWire - 1 year ago

SAN FRANCISCO, Aug. 27, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...

The Motley Fool - 1 year ago

Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?

The Motley Fool - 1 year ago

The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.

CNBC Television - 2 years ago

This biotech company is trying to stop or reverse age-related diseases

Keith Leonard, chairman and CEO of Unity Biotechnology, said that his company's mission is to extend the human "healthspan," the period in someone's life that is unburdened by disease or pain.

About UBX

Unity Biotechnology, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases. It is also developing programs in pulmonary disorders and ... [Read more...]

Industry
Biotechnology
IPO Date
May 3, 2018
CEO
Anirvan Ghosh
Employees
76
Stock Exchange
NASDAQ
Ticker Symbol
UBX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for UBX stock is "Hold." The 12-month stock price forecast is 5.67, which is a decrease of -12.36% from the latest price.

Price Target
$5.67
(-12.36% downside)
Analyst Consensus: Hold